Cardiac sympathetic dysinnervation in diabetes: Implications for enhanced cardiovascular risk

Circulation

Volumn 98, Issue 10, 1998, Pages 961-968

  Stevens, Martin J ^a,c   Raffel, David M ^a   Allman, Kevin C ^a   Dayanikli, Firat ^a   Ficaro, Edward ^a   Sandford, Tracy ^a   Wieland, Donald M ^a   Pfeifer, Michael A ^b   Schwaiger, Markus ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Diabetes mellitus; Imaging; Nervous system, autonomic; Ventricles

Indexed keywords

3 HYDROXYEPHEDRINE; CARBON 11; TRACER;

ADULT; AGED; ARTICLE; AUTONOMIC NEUROPATHY; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; FEMALE; HEART INNERVATION; HEART MUSCLE PERFUSION; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RISK ASSESSMENT; SYMPATHETIC INNERVATION;

EID: 0032497251     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.10.961     Document Type: Article

References (15)

1. Hilsted J, Jeensen SB. A simple test for autonomic neuropathy in juvenile diabetics. Acta Med Scand. 1979;205:385-387.
2. O'Brien OA, McFadden JP, Corrall RJM. The influence of autonomic neuropathy on mortality in insulin-dependent diabetes. Q J Med. 1991;290:495-502.
3. Rathman W, Ziegler D, Jahnke M, Haastert B, Gries FA. Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabet Med. 1993;10:820-824.
4. Ewing DJ, Campbell IW, Clarke BF. The natural history of diabetic autonomic neuropathy. Q J Med. 1980;49:95-108.
5. Page MM, Watkins PJ. The heart in diabetes: autonomic neuropathy and cardiomyopathy. Clin Endocrinol Metab. 1977;6:377-388.
6. Fava S, Azzopardi J, Muscatt HA, Fenech FF. Factors that influence outcome in diabetic subjects with myocardial infarction. Diabetes Care. 1993;16:1615-1618.
7. Zola B, Kahn JK, Juni JE, Vinik AI. Abnormal cardiac function in diabetic patients with autonomic neuropathy in the absence of ischemic heart disease. J Clin Endocrinol Metab. 1986;63:208-214.
8. Willich SN, Maclure M, Mittleman M, Arntz H-R, Muller JE. Sudden cardiac death: support for the role of triggering in causation. Circulation. 1993;87:1442-1450.
9. Lown B, Verrier RL. Neural activity and ventricular fibrillation. N Engl J Med. 1976;294:1165-1170.
10. Schwartz PJ, Randall WC, Anderson EA, Engel BT, Friedman M, Hartley LH, Pickering TG, Thoresen CE, for Task Force 4. Sudden cardiac death: nonpharmacologic interventions. Circulation. 1987;76(pt 2):I-215-I-219.
11. Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Malek I, Nyberg G, Ryden L, Swedberg K, Vedin A, Waagstein F, Waldenstrom A, Waldenstrom J, Wedel H, Wilhelmsen L, Wilhelmsson C. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomized trial. Lancet. 1981;2:123-127.
12. Beta-blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction, I: mortality results. JAMA. 1982;247:1707-1714.
13. Norwegian Multicentre Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981;304:801-807.
14. Australian and Swedish Pindolol Study Group. The effect of pindolol on the two year mortality after complicated myocardial infarction. Eur Heart J. 1983;4:367-375.
15. Mantysaari M, Kuikka J, Mustonen J, Tahvanainen K, Vanninen E, Lansimies E, Uusitupa M. Noninvasive detection of cardiac sympathetic nervous dysfunction in diabetic patients using [123]metaiodobenzylguanidine. Diabetes. 1992;41:1069-1075.